PANTELIS SKARLOS

Dr. PANTELIS SKARLOS

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Medicine
Verified
Journal Article
Open access
FSFoteini Simopoulou
Foteini Simopoulou
GKGeorge Kyrgias
George Kyrgias
IGIoannis Georgakopoulos
Ioannis Georgakopoulos
RARaphaela Avgousti
Raphaela Avgousti
CAChristina Armpilia
Christina Armpilia
AZAnna Zygogianni
Anna Zygogianni
Purpose: The current review aims to summarize the international experience of the impact of adaptive radiotherapy on dosimetry and clinical and toxicity outcomes. Additionally, it might trigger Radiation Oncologists to use ART and evaluate whether ART improves target volume coverage and/or normal tissue sparing and, consequently, therapeutic results. Materials and methods: We conducted an electronic literature search of PubMed/MEDLINE and ScienceDirect from January 2007 to January 2023. The search adhered to the PRISMA guidelines and employed keywords such as ART, HNC, parotid gland, and target volume. Furthermore, we examined the reference lists for studies pertinent to the present review. This study included both retrospective and prospective studies that were considered for inclusion. Conclusion: ART replanning appears to be a sustainable strategy to minimize toxicity by improving normal tissue sparing. Furthermore, it can enhance target volume coverage by correctly determining the specific dose to be delivered to the tumor. In conclusion, this review confirmed that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.

4 January 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
FSFoteini Simopoulou
Foteini Simopoulou
GKGeorge Kyrgias
George Kyrgias
IGIoannis Georgakopoulos
Ioannis Georgakopoulos
RARaphaela Avgousti
Raphaela Avgousti
CAChristina Armpilia
Christina Armpilia
AZAnna Zygogianni
Anna Zygogianni
We performed electronic research for articles published in PubMed, MEDLINE, and ScienceDirect databases from January 2004 to January 2023. The systematic review of twenty (20) peer-reviewed articles about dosimetric parameters and eight (8) articles about clinical outcomes confirmed the dosimetric advantages of ART through better target coverage and Organs at Risk (OARs) sparing, with subsequent benefits on decreased toxicity and improved clinical outcome, specifically local control of the disease. ART replanning is a sustainable strategy for minimizing toxicity by improving normal tissue sparing. Furthermore, it enhances target volume coverage by correctly determining the specific amount of dose to be delivered to the tumor. In conclusion, this review confirms that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.

17 June 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
GMGeorgios Maravelis
Georgios Maravelis
IKIoannis Koukourakis
Ioannis Koukourakis
PSPANTELIS SKARLOS
PANTELIS SKARLOS
Michael I. KoukourakisMichael I. Koukourakis
Michael I. Koukourakis
Despite technological advances in radiation therapy (RT), improvements in locoregional control of locally advanced disease remain limited, indicating a plateau in RT effectiveness. It is becoming increasingly clear that RT occurs within a dynamic metabolic microenvironment that merges oncogenic activity with metabolic and immune interactions. This includes responses to oxidative stress, regulation of cell death and survival signals, energy metabolism, protein synthesis, autophagy of molecules and organelles, and ultimately, the anti-tumor immune response. Each tumor, regardless of its histology, maintains a unique molecular and microenvironmental identity that influences its response to RT. Furthermore, RT acts as a cellular stressor that activates responses in cancer and stromal cells, impacting clinical outcomes. The concept of Metabolism and Immunity Adaptive Radiotherapy (M.I.A.R) recognizes that RT success depends not only on radiation dose and distribution but mainly on key interventions that alter and influence the biological environment before, during, and after therapy. It highlights the importance of an initial diagnostic workup, which is achievable with current tools, to identify tumor-specific oncogenes, metabolic, and immune profiles. Within the context of M.I.A.R., effective RT requires tumor preconditioning combined with concurrent use of drugs, including metabolism-targeting agents, to increase tumor sensitivity to radiation. Post-RT metabolic and immune interventions are essential for complete tumor eradication. This involves combining existing oncogene-targeting therapies with available immune treatments, supported by low-toxicity modulating drugs/agents with demonstrated preclinical activity against specific molecular and microenvironmental features. Overall, while MIAR remains a theoretical approach, existing preclinical and recent clinical data, e.g., those exploiting tumor hypoxia and re-oxygenation status, or post-RT immunotherapy, strongly support further dedicated investigation.

12 October 2026 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
EFElena Fountzilas
Elena Fountzilas
KPKYRIAKI PAPADOPOULOU
KYRIAKI PAPADOPOULOU
GKG.-A. Koliou
G.-A. Koliou
TPT. Papapavlou
T. Papapavlou
DPD. Pectasides
D. Pectasides
George FountzilasGeorge Fountzilas
George Fountzilas

16 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
PSPANTELIS SKARLOS
PANTELIS SKARLOS
IGIoannis Georgakopoulos
Ioannis Georgakopoulos
AKAndromachi Kougioumtzopoulou
Andromachi Kougioumtzopoulou
ZLZoi Liakouli
Zoi Liakouli
Kiki TheodorouKiki Theodorou
Kiki Theodorou
GMGeorge Maravelis
George Maravelis
Stage III/N2 non-small-cell lung cancer (NSCLC) can often be treated with either surgery-based multimodality therapy or definitive chemoradiotherapy. Historical randomized trials showed that surgery improved local control without demonstrating an overall-survival benefit; neither platform demonstrated superiority, although none was designed to establish equivalence. In the immunotherapy era, both pathways have improved through separate evidence streams: perioperative trials compared immunotherapy with chemotherapy-based surgical controls, and PACIFIC compared durvalumab with placebo after chemoradiotherapy. Neither stream determines which complete modern pathway is better for a patient eligible for both, and cross-trial comparisons are confounded by differences in populations, randomization points, and endpoint definitions. This review distinguishes three questions that are often conflated: whether direct comparative evidence exists, how large any relative treatment effect may be, and whether sufficient clinical equipoise exists to justify randomization. Technical resectability, physiological operability, and irradiability define eligibility for a platform, not comparative benefit, and no current biomarker has been shown to modify the relative effect of the two platforms. Comparative uncertainty is most visible in multistation, bulky, or anatomically complex N2 disease, the most practicable starting point for randomization; superiority of either platform, however, has not been demonstrated at either end of the N2 spectrum. A staged randomized comparison of the complete modern pathways, with prespecified analyses of candidate treatment-effect modifiers, is proposed as a reasoned research strategy.